---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000039"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-07-29T15:38:46+00:00"
generated_at: "2026-07-29T15:40:06.195382+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AbCellera announces collaboration with Vertex to develop T-cell engagers; receives $281M upfront

## Summary
- Collaboration with Vertex (VRTX) to discover multispecific T-cell engagers for autoimmune diseases and other conditions.
- AbCellera leads discovery and early development; Vertex funds all R&D costs and holds commercialization rights.
- AbCellera receives $281 million in total upfront payments, plus preclinical, development, regulatory, and commercial milestones and tiered royalties.
- AbCellera may also perform cell line development, process development, and clinical manufacturing through Phase 1 for any program.

## SEC filing metadata
- accession: 0001703057-26-000039
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-07-29T15:38:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/0001703057-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/abcl-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000039
- JSON: https://secwatch.observer/filing/0001703057-26-000039.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.